Guggenheim Capital LLC Dyne Therapeutics, Inc. Call Options Transaction History
Guggenheim Capital LLC
- $12 Billion
- Q4 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding DYN
# of Institutions
213Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$112 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$103 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$103 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$93.3 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$88.8 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $720M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...